Advertisement

Orthopedic

Advertisement

In a recent press release, Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced that the U.S. Food and Drug Administration (FDA) approved Zilretta™ (triamcinolone acetonide extended-release injectable suspension), the first and only extended-release, intra-articular injection for osteoarthritis knee pain.

Advertisement